SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hem
Related
Share this page
Guest Posts by Easy BranchesGet Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.